For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com  Inclusion Criteria:  Qualify as having Systemic Lupus Erythematosus (SLE), according to the SLE International Collaborating Clinics (SLICC) Classification Criteria ≥ 12 weeks before the screening visit Test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody>/= 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or anti-Smith antibody. Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥ 6 points and clinical Hybrid SLEDAI score ≥ 4 points with joint involvement and/or rash  Exclusion Criteria:  Active severe lupus nephritis (LN) as assessed by the investigator Neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is not SLE Antiphospholipid Syndrome  Other protocol-defined inclusion/exclusion criteria apply